Fluconazole (UK-49,858) treatment of candidiasis in normal and diabetic rats.
AUTOR(ES)
Fisher, M A
RESUMO
Fluconazole (UK-49,858), a new oral bistriazole antifungal agent, was compared with amphotericin B in the treatment of established systemic infection with Candida albicans in normal and diabetic rats. In normal rats, oral fluconazole at 10 mg/kg per day for 7 days reduced Candida colony counts in the kidneys and livers as well as amphotericin B did and was nearly as effective as amphotericin B in a 21-day treatment trial. There was no further reduction in Candida colony counts when normal rats were treated with fluconazole at 40 mg/kg twice a day for 7 days. In streptozotocin-induced diabetic rats, fluconazole at 20 mg/kg per day for either 7 or 21 days compared favorably with amphotericin B in efficacy. Results of our study suggest that oral fluconazole may be useful in the treatment of established disseminated candidiasis in normal as well as diabetic hosts.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=176059Documentos Relacionados
- Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice.
- Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo.
- Activities of fluconazole (UK 49,858) and ketoconazole against ketoconazole-susceptible and -resistant Candida albicans.
- Comparative activities of UK-49,858 and amphotericin B against Blastomyces dermatitidis infections in mice.
- Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans.
